ClinicalTrials.Veeva

Menu

Characterization of Bleeding Disorders in EDS

University Health Network, Toronto logo

University Health Network, Toronto

Status

Invitation-only

Conditions

Vascular EDS (vEDS)
Classical Ehlers-Danlos Syndrome
Ehlers-Danlos Syndrome
Classical EDS (cEDS)
Hypermobile Ehlers-Danlos Syndrome
EDS
Vascular Ehlers-Danlos Syndrome
Hypermobile EDS (hEDS)

Treatments

Other: 20 ml venous blood collection

Study type

Observational

Funder types

Other

Identifiers

NCT05434728
21-5787.0

Details and patient eligibility

About

Ehlers-Danlos Syndrome (EDS) is a disease that weakens the connective tissues (i.e. tendons and ligaments) in the human body. EDS can make the joints loose and alter skin and wound healing. It can also weaken blood vessels and organs. Many EDS patients are referred for investigation of bleeding symptoms. Although most patients will have mild symptoms such as bruising, many will experience significant bleeding that can be life-threatening. The physiological reason behind this has not been identified and therefore, treating this is challenging. In addition, patients with EDS frequently require major surgery due to complications from their connective tissue disease. These surgery carries a significant risk of catastrophic bleeding which is further magnified in this group of patients. The specific reason of clinical bleeding in patients with EDS is likely multifactorial, including skin and blood vessel fragility leading to increased bruising and poor wound healing, coagulopathies related to factor deficiency, acquired vonWillebrand disease (VWD), and notable platelet dysfunction.

Despite compelling preliminary evidence, there is limited data on the diagnosis and management of platelet dysfunction in EDS patients. Therefore, in this study we will characterize hemostasis, the medical term which refers to the process of stopping blood flow, across the three most common subtypes of EDS.we will also determine the burden of illness of pathologic bleeding in patients with Ehlers-Danlos Syndrome (EDS) using validated patient reported tools.

Enrollment

45 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Any adult (≥ 18 years) patient with a known diagnosis of Ehlers Danlos Syndrome (Subtypes Classical, Hypermobile, or Vascular) as per the 2017 International Classification of Ehlers Danlos Syndrome.

Exclusion criteria

  • Subtypes of Ehlers Danlos Syndrome which are not Classical, Hypermobile, or Vascular.
  • Unable or unwilling to consent for the study

Trial design

45 participants in 3 patient groups

Hypermobile EDS
Description:
Individuals with a confirmed diagnosis of hypermobile EDS
Treatment:
Other: 20 ml venous blood collection
Classical EDS
Description:
Individuals with a confirmed diagnosis of classical EDS
Treatment:
Other: 20 ml venous blood collection
Vascular EDS
Description:
Individuals with a confirmed diagnosis of vascular EDS
Treatment:
Other: 20 ml venous blood collection

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems